Piper Jaffray Starts Voyager Therapeutics (VYGR) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St muted after Fed Chair Warsh's speech; AI rally cools
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil drifts lower as Hormuz flows balance slow progress in Iran diplomacy
- Dollar climbs after Warsh comments, poised for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- BioNTech ends colorectal cancer mRNA therapy trial early
Chardan Capital Markets Starts Voyager Therapeutics (VYGR) at Sell
December 9, 2015 9:55 AM ESTChardan Capital Markets initiated coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Sell rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.
Shares of Voyager Therapeutics closed at $30.11 yesterday.
... MoreWedbush Starts Voyager Therapeutics (VYGR) at Outperform
December 7, 2015 7:42 AM ESTWedbush initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Outperform rating and a price target of $36.00.
Analyst David Nierengarten highlighted:
Pioneering AAV-based gene therapy for serious diseases of the central nervous system (CNS). VYGR has selected a number of CNS diseases with validated, specific gene targets that are amenable to AAV gene therapy. The CNS represents an ideal site for gene therapy due to its immune privilege status and terminally-differentiated cells that allow long-term transgene... MoreCowen Starts Voyager Therapeutics (VYGR) at Outperform
December 7, 2015 6:30 AM ESTCowen initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Outperform rating.
Analyst Phil Nadeau commented, "Voyagers lead program is VY-AADC01 for the treatment of advanced Parkinsons disease which is on track to produce proof-of-concept data in 2016. We estimate that VY-AADC01... More
